Abacavir 300mg
| Product Overview | |
| Generic Name | Abacavir 300mg |
| Brand Name(s) | Ziagen®, Abamune, Trizivir (combination), Abec |
| Form | Film-coated tablet |
| Strength | 300mg |
| Therapeutic Class | Nucleoside reverse transcriptase inhibitor |
| ATC Code | J05AR01 |
| Manufacturing & Regulatory | |
| Manufacturer | Multiple |
| Country | India/USA/EU |
| GMP Compliance | WHO/cGMP-compliant |
| DMF/CEP | Type II |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 20 packs |
| Shelf Life | 24 Months |
| Storage | Store at 20–25 °C (room temperature), keep dry/cool |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Provided per batch |
| SDS | MSDS per international standards |
| CTD Summary | available from WHO‑GMP manufacturers upon significant orders |
Description
Indications & Usage: indicated for the treatment of HIV‑1 infection, to be used as part of combination antiretroviral therapy. It inhibits reverse transcriptase, preventing viral DNA synthesis. Not recommended for patients positive for HLA‑B*5701 allele due to risk of hypersensitivity. It’s contraindicated in moderate to severe hepatic impairment; dosage adjustment needed in mild hepatic dysfunction. Also available in pediatric formulations like oral solution.
